Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing safety study of Walrinvax bivalent HPV vaccine in females aged 9-30 years in Chongqing
CTR20253239Phase 4Completed
- Sponsor
- Yuxi Zerun Biotechnology Co., Ltd.
- Start
- Sep 2025
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of human papillomavirus 16/18 bivalent vaccine in human papillomavirus infection, Cervical Cancer (CC), cervical intraepithelial neoplasia (CIN), cervical adenocarcinoma in situ (AIS), sponsored by Yuxi Zerun Biotechnology Co., Ltd.. Started Sep 2025; status: completed.
02
Drugs
human papillomavirus 16/18 bivalent vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)cervical intraepithelial neoplasia (CIN)cervical adenocarcinoma in situ (AIS)
Beyond the preview
Go deeper on CTR20253239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253239.